Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Status:
Completed
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
The primary objective is to determine whether daily dosing with NYX-2925 changes markers of
central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain,
and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function
connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy
(H-MRS) in fibromyalgia subjects on active drug versus placebo.